Genetically-engineered

Aihua WU; Yingzhi Chen; Hairui Wang; Ya Chang; Meng Zhang; Pengfei Zhao; Yisi Tang; Qin XU; Zhuangzhi Zhu; Yang Cao; Yongzhuo Huang

Return

Genetically-engineered "all-in-one" vaccine platform for cancer immunotherapy.

Author: Aihua WU ¹ ; Yingzhi CHEN ¹ ; Hairui WANG ¹ ; Ya CHANG ¹ ; Meng ZHANG ¹ ; Pengfei ZHAO ¹ ; Yisi TANG ¹ ; Qin XU ² ; Zhuangzhi ZHU ³ ; Yang CAO ² ; Yongzhuo HUANG ¹
Author Information

1. State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
2. Artemisinin Research Center, the First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou 510450, China.
3. National Pharmaceutical Engineering Research Center, China State Institute of Pharmaceutical Industry, Shanghai 201203, China.
Publication Type:Journal Article
Keywords: Adjuvant; Cancer vaccine; Legumain; Protein engineering; TRP2; Transcutaneous immunization; Trichosanthin
From: Acta Pharmaceutica Sinica B 2021;11(11):3622-3635
CountryChina
Language:English
Abstract: An essential step for cancer vaccination is to break the immunosuppression and elicit a tumor-specific immunity. A major hurdle against cancer therapeutic vaccination is the insufficient immune stimulation of the cancer vaccines and lack of a safe and efficient adjuvant for human use. We discovered a novel cancer immunostimulant, trichosanthin (TCS), that is a clinically used protein drug in China, and developed a well-adaptable protein-engineering method for making recombinant protein vaccines by fusion of an antigenic peptide, TCS, and a cell-penetrating peptide (CPP), termed an "all-in-one" vaccine, for transcutaneous cancer immunization. The TCS adjuvant effect on antigen presentation was investigated and the antitumor immunity of the vaccines was investigated using the different tumor models. The vaccines were prepared